10/31/14 MDVN 105.70 Medivation Inc $MDVN Hit a 52
Post# of 71
Posted On: 11/02/2014 1:15:44 AM
10/31/14 MDVN 105.70 Medivation Inc $MDVN Hit a 52 week high of 108.83 Closing the day 10/31/14 at 105.70 +2.96 +2.88% With a day low of 103.21 and a total volume of 1,577,400.
MDVN Recent Posts: http://investorshangout.com/Medivation-MDVN-54728/
MDVN Medivation Inc Recent Headline News
Acorda (ACOR) Beats on Q3 Earnings, Ups Ampyra Outlook - Analyst Blog
Arpita Dutt - Zacks Investment Research - Fri Oct 31, 12:20PM CDT
Acorda (ACOR) which recently acquired Civitas Therapeutics, is working on reprioritizing its pipeline.
MDVN: 105.70 (+2.96), BIIB: 321.08 (+0.08), NLNK: 32.65 (-1.23), ACOR: 34.82 (-1.33)
3 Scary Stocks to Avoid
Todd Campbell, The Motley Fool - Motley Fool - Fri Oct 31, 11:55AM CDT
Source: Flickr user Mike Poresky Goblins came to Wall Street early this year when markets flirted with a crash in the beginning of October. As a result, a frightening dip in account values may have many investors tossing and turning at night...
MDVN: 105.70 (+2.96), JNJ: 107.78 (+0.74), INSY: 40.67 (-1.32), GWPH: 73.75 (+3.29), DNDN: 0.98 (-0.05), SNY: 46.24 (+0.54), MNKD: 6.01 (-0.07)
AMAG Up on Q3 Earnings Beat, Revenues Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 9:57AM CDT
AMAG Pharmaceuticals (AMAG) reported third-quarter 2014 earnings of 6 cents per share as compared to a loss of 1 cent per share incurred in the year-ago quarter.
MDVN: 105.70 (+2.96), BIIB: 321.08 (+0.08), AMAG: 33.01 (-0.95)
Incyte (INCY) Looks Good: Stock Moves 10.9% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 8:46AM CDT
Incyte (INCY) was a big mover last session, with shares rising nearly 11% on the day.
MDVN: 105.70 (+2.96), BIIB: 321.08 (+0.08), INCY: 67.06 (+2.88), ILMN: 192.58 (-0.84)
Bristol-Myers Squibb (BMY) Jumps: Stock Moves Up 8.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 8:39AM CDT
Bristol-Myers Squibb Company (BMY) was a big mover last session, as its shares rose nearly 9% on the day.
MDVN: 105.70 (+2.96), MACK: 9.17 (-0.11), ILMN: 192.58 (-0.84), BMY: 58.19 (-0.79)
Novo Nordisk A/S (NVO) Shows Strength: Stock Up 6.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 7:51AM CDT
Novo Nordisk A/S (NVO) was a big mover last session, as its shares rose over 6% on the day.
MDVN: 105.70 (+2.96), MACK: 9.17 (-0.11), NVO: 45.18 (-1.03), ILMN: 192.58 (-0.84)
Medivation and Astellas Announce Phase 3 Study of Enzalutamide in Men With High-Risk, Hormone-Sensitive, Non-Metastatic Prostate Cancer That Has Recurred Following Definitive Local Therapy
Marketwired - Thu Oct 30, 10:00PM CDT
Medivation Inc. (NASDAQ: MDVN) and Astellas today announced plans to initiate a global Phase 3 clinical trial that will evaluate the efficacy and safety of enzalutamide in patients with high-risk, hormone-sensitive, non-metastatic prostate cancer that has biochemically recurred (rising prostate-specific antigen [PSA] level) following definitive local therapy with radical prostatectomy and/or radiation therapy. Currently there is no prescription medicine specifically approved in the United States for these patients.
MDVN: 105.70 (+2.96)
Cara Therapeutics (CARA) Worth Watching: Stock Rises 6.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 8:39AM CDT
Cara Therapeutics Inc. (CARA) was a big mover last session, as its shares rose over 6% on the day.
MDVN: 105.70 (+2.96), MACK: 9.17 (-0.11), CARA: 9.01 (-0.18), ILMN: 192.58 (-0.84)
Oncolytics Biotech (ONCY) Looks Good: Stock Soars 26% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 8:25AM CDT
Oncolytics Biotech (ONCY) was a big mover last session, with shares surging almost 26% on the day.
MDVN: 105.70 (+2.96), BIIB: 321.08 (+0.08), ONCY: 1.00 (+0.18), ILMN: 192.58 (-0.84)
ANI Pharmaceuticals (ANIP) Shows Strength: Stock Up 6.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 7:51AM CDT
ANI Pharmaceuticals was a big mover last session, as its shares rose almost 7% on the day.
MDVN: 105.70 (+2.96), MACK: 9.17 (-0.11), ANIP: 33.96 (+0.91), ILMN: 192.58 (-0.84)
Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma
PR Newswire - Thu Oct 30, 7:40AM CDT
Investor-Edge has initiated coverage on the following equities: Organovo Holdings Inc. (NYSE MKT: ONVO), Medivation Inc. (NASDAQ: MDVN), Pharmacyclics Inc. (NASDAQ: PCYC), Synthetic Biologics Inc. (NYSE MKT: SYN), and Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Wednesday, October 29, 2014, the NASDAQ Composite ended at 4,549.23, down 0.33%, the Dow Jones Industrial Average declined 0.18%, to finish the day at 16,974.31, and the S&P 500 closed at 1,982.30, down 0.14%. The losses were broad based as seven out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 761.13, up 0.03%, with the index also advancing 6.25% in the previous three months. Register for your complimentary reports on these five stocks at:
MDVN: 105.70 (+2.96), SYN: 1.51 (-0.06), PCYC: 130.67 (-3.93), IRWD: 14.02 (-0.15), ONVO: 6.54 (+0.11)
Amgen Up on Strategic Initiatives and 2015 Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 2:05PM CDT
Amgen (AMGN) provided a comprehensive review of its strategic plans, growth objectives and capital allocation in a business review meeting.
MDVN: 105.70 (+2.96), BIIB: 321.08 (+0.08), ILMN: 192.58 (-0.84), AMGN: 162.18 (+0.60)
Vertex Pharmaceuticals Posts Narrower-than-Expected Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 12:00PM CDT
Vertex Pharmaceuticals's (VRTX) third-quarter 2014 loss came in at 56 cents per share wider than the year-ago loss of 46 cents.
MDVN: 105.70 (+2.96), BIIB: 321.08 (+0.08), JNJ: 107.78 (+0.74), VRTX: 112.64 (+1.79)
The Medicines Company (MDCO) Jumps: Stock Gains 16.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 8:25AM CDT
The Medicines Company (MDCO) was a big mover last session, with shares rising nearly 17% on the day.
MDVN: 105.70 (+2.96), BIIB: 321.08 (+0.08), MDCO: 25.32 (-0.34), ILMN: 192.58 (-0.84)
Medivation Announces Participation at Upcoming Investor Conference
Marketwired - Tue Oct 28, 3:12PM CDT
Medivation, Inc. (NASDAQ: MDVN) today announced that it will present at the following conference:
MDVN: 105.70 (+2.96)
Novavax (NVAX) in Focus: Stock Rises 13% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Oct 28, 7:44AM CDT
Novavax (NVAX) was a big mover last session, as the company saw its shares surge over 13% on the day.
MDVN: 105.70 (+2.96), ONCY: 1.00 (+0.18), NVAX: 5.60 (-0.03), ILMN: 192.58 (-0.84)
Will WellPoint (WLP) Surpass Q3 Earnings Estimates? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 27, 2:00PM CDT
WellPoint Inc. (WLP) is set to report third-quarter 2014 earnings results on Oct 29, 2014.
MDVN: 105.70 (+2.96), AMSG: 54.01 (+0.96), CRL: 63.16 (+0.35), WLP: 126.69 (+3.40)
Verastem (VSTM) Shows Strength: Stock Adds 7% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 27, 8:39AM CDT
Verastem, Inc. (VSTM) was a big mover last session, as its shares rose a little over 7% on the day.
MDVN: 105.70 (+2.96), MACK: 9.17 (-0.11), VSTM: 9.49 (-0.31), ILMN: 192.58 (-0.84)
BioMarin Pharmaceutical (BMRN) Jumps: Stock Rises 8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 27, 7:51AM CDT
BioMarin Pharmaceutical Inc. (BMRN) was a big mover last session, as its shares rose a little over 8% on the day.
MDVN: 105.70 (+2.96), MACK: 9.17 (-0.11), BMRN: 82.50 (+0.14), ILMN: 192.58 (-0.84)
3 Biotech Stocks Growing Faster Than Gilead Sciences Inc.
Todd Campbell, The Motley Fool - Motley Fool - Mon Oct 27, 7:03AM CDT
Source: Celgene. Gilead Sciences has captured investors' attention this year thanks to wildly impressive sales of its hepatitis C drug Sovaldi, but the company is by no means the only fast-growing big biotech out there. Gilead's bottom line...
MDVN: 105.70 (+2.96), JNJ: 107.78 (+0.74), BIIB: 321.08 (+0.08), GILD: 112.00 (-2.22), NVS: 92.69 (+0.74), CELG: 107.09 (+0.15)
MDVN Recent Posts: http://investorshangout.com/Medivation-MDVN-54728/
MDVN Medivation Inc Recent Headline News
Acorda (ACOR) Beats on Q3 Earnings, Ups Ampyra Outlook - Analyst Blog
Arpita Dutt - Zacks Investment Research - Fri Oct 31, 12:20PM CDT
Acorda (ACOR) which recently acquired Civitas Therapeutics, is working on reprioritizing its pipeline.
MDVN: 105.70 (+2.96), BIIB: 321.08 (+0.08), NLNK: 32.65 (-1.23), ACOR: 34.82 (-1.33)
3 Scary Stocks to Avoid
Todd Campbell, The Motley Fool - Motley Fool - Fri Oct 31, 11:55AM CDT
Source: Flickr user Mike Poresky Goblins came to Wall Street early this year when markets flirted with a crash in the beginning of October. As a result, a frightening dip in account values may have many investors tossing and turning at night...
MDVN: 105.70 (+2.96), JNJ: 107.78 (+0.74), INSY: 40.67 (-1.32), GWPH: 73.75 (+3.29), DNDN: 0.98 (-0.05), SNY: 46.24 (+0.54), MNKD: 6.01 (-0.07)
AMAG Up on Q3 Earnings Beat, Revenues Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 9:57AM CDT
AMAG Pharmaceuticals (AMAG) reported third-quarter 2014 earnings of 6 cents per share as compared to a loss of 1 cent per share incurred in the year-ago quarter.
MDVN: 105.70 (+2.96), BIIB: 321.08 (+0.08), AMAG: 33.01 (-0.95)
Incyte (INCY) Looks Good: Stock Moves 10.9% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 8:46AM CDT
Incyte (INCY) was a big mover last session, with shares rising nearly 11% on the day.
MDVN: 105.70 (+2.96), BIIB: 321.08 (+0.08), INCY: 67.06 (+2.88), ILMN: 192.58 (-0.84)
Bristol-Myers Squibb (BMY) Jumps: Stock Moves Up 8.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 8:39AM CDT
Bristol-Myers Squibb Company (BMY) was a big mover last session, as its shares rose nearly 9% on the day.
MDVN: 105.70 (+2.96), MACK: 9.17 (-0.11), ILMN: 192.58 (-0.84), BMY: 58.19 (-0.79)
Novo Nordisk A/S (NVO) Shows Strength: Stock Up 6.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 7:51AM CDT
Novo Nordisk A/S (NVO) was a big mover last session, as its shares rose over 6% on the day.
MDVN: 105.70 (+2.96), MACK: 9.17 (-0.11), NVO: 45.18 (-1.03), ILMN: 192.58 (-0.84)
Medivation and Astellas Announce Phase 3 Study of Enzalutamide in Men With High-Risk, Hormone-Sensitive, Non-Metastatic Prostate Cancer That Has Recurred Following Definitive Local Therapy
Marketwired - Thu Oct 30, 10:00PM CDT
Medivation Inc. (NASDAQ: MDVN) and Astellas today announced plans to initiate a global Phase 3 clinical trial that will evaluate the efficacy and safety of enzalutamide in patients with high-risk, hormone-sensitive, non-metastatic prostate cancer that has biochemically recurred (rising prostate-specific antigen [PSA] level) following definitive local therapy with radical prostatectomy and/or radiation therapy. Currently there is no prescription medicine specifically approved in the United States for these patients.
MDVN: 105.70 (+2.96)
Cara Therapeutics (CARA) Worth Watching: Stock Rises 6.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 8:39AM CDT
Cara Therapeutics Inc. (CARA) was a big mover last session, as its shares rose over 6% on the day.
MDVN: 105.70 (+2.96), MACK: 9.17 (-0.11), CARA: 9.01 (-0.18), ILMN: 192.58 (-0.84)
Oncolytics Biotech (ONCY) Looks Good: Stock Soars 26% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 8:25AM CDT
Oncolytics Biotech (ONCY) was a big mover last session, with shares surging almost 26% on the day.
MDVN: 105.70 (+2.96), BIIB: 321.08 (+0.08), ONCY: 1.00 (+0.18), ILMN: 192.58 (-0.84)
ANI Pharmaceuticals (ANIP) Shows Strength: Stock Up 6.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 7:51AM CDT
ANI Pharmaceuticals was a big mover last session, as its shares rose almost 7% on the day.
MDVN: 105.70 (+2.96), MACK: 9.17 (-0.11), ANIP: 33.96 (+0.91), ILMN: 192.58 (-0.84)
Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma
PR Newswire - Thu Oct 30, 7:40AM CDT
Investor-Edge has initiated coverage on the following equities: Organovo Holdings Inc. (NYSE MKT: ONVO), Medivation Inc. (NASDAQ: MDVN), Pharmacyclics Inc. (NASDAQ: PCYC), Synthetic Biologics Inc. (NYSE MKT: SYN), and Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Wednesday, October 29, 2014, the NASDAQ Composite ended at 4,549.23, down 0.33%, the Dow Jones Industrial Average declined 0.18%, to finish the day at 16,974.31, and the S&P 500 closed at 1,982.30, down 0.14%. The losses were broad based as seven out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 761.13, up 0.03%, with the index also advancing 6.25% in the previous three months. Register for your complimentary reports on these five stocks at:
MDVN: 105.70 (+2.96), SYN: 1.51 (-0.06), PCYC: 130.67 (-3.93), IRWD: 14.02 (-0.15), ONVO: 6.54 (+0.11)
Amgen Up on Strategic Initiatives and 2015 Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 2:05PM CDT
Amgen (AMGN) provided a comprehensive review of its strategic plans, growth objectives and capital allocation in a business review meeting.
MDVN: 105.70 (+2.96), BIIB: 321.08 (+0.08), ILMN: 192.58 (-0.84), AMGN: 162.18 (+0.60)
Vertex Pharmaceuticals Posts Narrower-than-Expected Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 12:00PM CDT
Vertex Pharmaceuticals's (VRTX) third-quarter 2014 loss came in at 56 cents per share wider than the year-ago loss of 46 cents.
MDVN: 105.70 (+2.96), BIIB: 321.08 (+0.08), JNJ: 107.78 (+0.74), VRTX: 112.64 (+1.79)
The Medicines Company (MDCO) Jumps: Stock Gains 16.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 8:25AM CDT
The Medicines Company (MDCO) was a big mover last session, with shares rising nearly 17% on the day.
MDVN: 105.70 (+2.96), BIIB: 321.08 (+0.08), MDCO: 25.32 (-0.34), ILMN: 192.58 (-0.84)
Medivation Announces Participation at Upcoming Investor Conference
Marketwired - Tue Oct 28, 3:12PM CDT
Medivation, Inc. (NASDAQ: MDVN) today announced that it will present at the following conference:
MDVN: 105.70 (+2.96)
Novavax (NVAX) in Focus: Stock Rises 13% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Oct 28, 7:44AM CDT
Novavax (NVAX) was a big mover last session, as the company saw its shares surge over 13% on the day.
MDVN: 105.70 (+2.96), ONCY: 1.00 (+0.18), NVAX: 5.60 (-0.03), ILMN: 192.58 (-0.84)
Will WellPoint (WLP) Surpass Q3 Earnings Estimates? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 27, 2:00PM CDT
WellPoint Inc. (WLP) is set to report third-quarter 2014 earnings results on Oct 29, 2014.
MDVN: 105.70 (+2.96), AMSG: 54.01 (+0.96), CRL: 63.16 (+0.35), WLP: 126.69 (+3.40)
Verastem (VSTM) Shows Strength: Stock Adds 7% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 27, 8:39AM CDT
Verastem, Inc. (VSTM) was a big mover last session, as its shares rose a little over 7% on the day.
MDVN: 105.70 (+2.96), MACK: 9.17 (-0.11), VSTM: 9.49 (-0.31), ILMN: 192.58 (-0.84)
BioMarin Pharmaceutical (BMRN) Jumps: Stock Rises 8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 27, 7:51AM CDT
BioMarin Pharmaceutical Inc. (BMRN) was a big mover last session, as its shares rose a little over 8% on the day.
MDVN: 105.70 (+2.96), MACK: 9.17 (-0.11), BMRN: 82.50 (+0.14), ILMN: 192.58 (-0.84)
3 Biotech Stocks Growing Faster Than Gilead Sciences Inc.
Todd Campbell, The Motley Fool - Motley Fool - Mon Oct 27, 7:03AM CDT
Source: Celgene. Gilead Sciences has captured investors' attention this year thanks to wildly impressive sales of its hepatitis C drug Sovaldi, but the company is by no means the only fast-growing big biotech out there. Gilead's bottom line...
MDVN: 105.70 (+2.96), JNJ: 107.78 (+0.74), BIIB: 321.08 (+0.08), GILD: 112.00 (-2.22), NVS: 92.69 (+0.74), CELG: 107.09 (+0.15)
(0)
(0)